Immunovant, Inc. (NASDAQ:IMVT) Insider Michael Geffner Sells 3,261 Shares

Immunovant, Inc. (NASDAQ:IMVT) insider Michael Geffner sold 3,261 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $28.90, for a total transaction of $94,242.90. Following the completion of the sale, the insider now directly owns 141,616 shares in the company, valued at $4,092,702.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Immunovant Price Performance

IMVT traded down $0.58 during midday trading on Friday, reaching $27.17. 1,411,695 shares of the company’s stock were exchanged, compared to its average volume of 1,224,262. The stock has a market capitalization of $3.95 billion, a PE ratio of -14.77 and a beta of 0.65. The business’s 50-day moving average price is $32.30 and its 200 day moving average price is $35.86. Immunovant, Inc. has a 1-year low of $15.90 and a 1-year high of $45.58.

Immunovant (NASDAQ:IMVT) last issued its earnings results on Monday, February 12th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. As a group, analysts expect that Immunovant, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Immunovant in a research report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of Immunovant in a research report on Tuesday, February 20th. They issued an “overweight” rating and a $51.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research report on Friday, January 12th. Oppenheimer started coverage on shares of Immunovant in a research report on Thursday, March 28th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Wolfe Research started coverage on shares of Immunovant in a research report on Thursday, February 15th. They set an “outperform” rating and a $55.00 price objective on the stock. Seventeen analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $48.00.

Institutional Trading of Immunovant

A number of large investors have recently modified their holdings of the company. FMR LLC increased its holdings in shares of Immunovant by 47.5% in the 3rd quarter. FMR LLC now owns 7,748,546 shares of the company’s stock worth $297,467,000 after acquiring an additional 2,494,678 shares during the period. Vanguard Group Inc. increased its holdings in shares of Immunovant by 14.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock worth $239,290,000 after acquiring an additional 764,530 shares during the period. Point72 Asset Management L.P. bought a new position in Immunovant in the 4th quarter valued at about $112,356,000. Armistice Capital LLC grew its position in Immunovant by 38.6% in the 4th quarter. Armistice Capital LLC now owns 1,436,000 shares of the company’s stock valued at $60,499,000 after buying an additional 400,123 shares in the last quarter. Finally, Fred Alger Management LLC grew its position in Immunovant by 6,108.9% in the 3rd quarter. Fred Alger Management LLC now owns 1,186,031 shares of the company’s stock valued at $45,532,000 after buying an additional 1,166,929 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.